← All trials
NCT04882735
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2021
- Primary completion
- Sep 30, 2026
- Completion date
- Oct 31, 2026
- First posted
- May 12, 2021
- Last posted
- May 17, 2021
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Eidos Therapeutics, Inc.Lead sponsor
- Eidos Therapeutics, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.